Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

帕博西利布 富维斯特朗 医学 依西美坦 来曲唑 芳香化酶抑制剂 阿那曲唑 内科学 肿瘤科 乳腺癌 临床终点 转移性乳腺癌 芳香化酶 妇科 癌症 临床试验 雌激素受体
作者
François‐Clément Bidard,Anne‐Claire Hardy‐Bessard,Florence Dalenc,Thomas Bachelot,Jean‐Yves Pierga,Thibault De La Motte Rouge,Renaud Sabatier,Coraline Dubot,Jean‐Sébastien Frénel,Jean Marc Ferrero,Sylvain Ladoire,Christelle Lévy,Marie‐Ange Mouret‐Reynier,Alain Lortholary,Julien Grenier,Camille Chakiba,Laetitia Stefani,Jérôme Edouard Plaza,Florian Clatot,Luís Teixeira
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (11): 1367-1377 被引量:197
标识
DOI:10.1016/s1470-2045(22)00555-1
摘要

In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and palbociclib.We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete.From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related.PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials.Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
mzhmhy发布了新的文献求助10
3秒前
李健的粉丝团团长应助ASA采纳,获得30
4秒前
Choi完成签到,获得积分0
4秒前
无辜如容发布了新的文献求助10
4秒前
123完成签到,获得积分10
5秒前
6秒前
单耳兔完成签到 ,获得积分10
6秒前
潇湘雪月发布了新的文献求助10
6秒前
故意的靳完成签到,获得积分10
8秒前
mzhmhy完成签到,获得积分10
8秒前
bkagyin应助wish采纳,获得10
12秒前
Afaq发布了新的文献求助10
12秒前
果粒多发布了新的文献求助10
13秒前
13秒前
无辜如容完成签到,获得积分10
14秒前
14秒前
17秒前
18秒前
ASA发布了新的文献求助30
18秒前
19秒前
情怀应助tingting9采纳,获得10
20秒前
FXQ123_范发布了新的文献求助10
20秒前
sun完成签到,获得积分20
20秒前
22秒前
彭于晏应助wldsd采纳,获得30
22秒前
量子星尘发布了新的文献求助10
22秒前
23秒前
23秒前
高一淼发布了新的文献求助10
24秒前
明道若昧完成签到,获得积分10
24秒前
上官若男应助mk采纳,获得10
25秒前
wish完成签到,获得积分10
27秒前
wish发布了新的文献求助10
29秒前
稍等一下完成签到 ,获得积分10
30秒前
momo发布了新的文献求助10
30秒前
32秒前
32秒前
liang白开完成签到,获得积分10
34秒前
mk发布了新的文献求助10
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136